Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune ClassifierBusiness Wire • 06/27/23
Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual MeetingBusiness Wire • 06/01/23
Biodesix to Participate in William Blair's 43rd Annual Growth Stock ConferenceBusiness Wire • 05/31/23
Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® TestingBusiness Wire • 05/25/23
Biodesix, Inc. Chief Financial Officer Robin Harper Cowie Appointed to Colorado BioScience Association's Board of DirectorsBusiness Wire • 05/24/23
Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International ConferenceBusiness Wire • 05/18/23
Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and HighlightsBusiness Wire • 03/06/23
Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023Business Wire • 02/21/23
Biodesix Announces First Four Private Payer Coverage Policies for the Nodify XL2® TestBusiness Wire • 12/19/22
Biodesix Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of DirectorsBusiness Wire • 12/16/22
Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review MagazineBusiness Wire • 12/12/22
Biodesix Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesBusiness Wire • 11/21/22
Biodesix Announces Pricing of $35.1 Million Upsized Public Offering of Common StockBusiness Wire • 11/17/22
Biodesix Announces Senior Secured Financing Agreement with Perceptive Advisors for Up to $50 MillionBusiness Wire • 11/16/22
Biodesix Presents New Data from the INSIGHT Study at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingBusiness Wire • 11/10/22